Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

AMGN Sep 2024 410.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0400

0.0000

(0.00%)

As of 03:47PM EDT. Market open.

Loading interactive chart…

Zacks
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
PR Newswire
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.